Mironid
eDR62Effective DR: 62/100. Below median. Measured by StartupHub.ai. Median 68.Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
About
Mironid is a biopharmaceutical company focused on developing first-in-class LoAc small molecule drug candidates that directly target the central signaling mechanism driving Autosomal Dominant Polycystic Kidney Disease (ADPKD). Their lead candidate, MR-L45, aims to reduce cyst formation and growth by activating long-form PDE4 enzymes, increasing the breakdown of cAMP, and offering a differentiated treatment option for patients with limited alternatives.
Key facts
At-a-glance profile data
- Website
- mironid.com
- Headquarters
- Glasgow, United Kingdom
- Founded
- 2015
- Employees
- 16
- Total funding
- $46M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Aug 2026 | Series B | $46M | Scottish National Investment Bank |
Frequently asked
What is Mironid's Effective Domain Rating?
StartupHub's Effective Domain Rating for Mironid is 62 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is underrated against its Ahrefs Domain Rating of 12, meaning it surfaces in search and AI results more than its claimed authority alone would suggest.
Is Mironid trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Mironid is 61 out of 100, based on site security posture and privacy practices.
How much funding has Mironid raised?
Mironid has raised a total of $46M in funding. The most recent round on record is Series B.
How many employees does Mironid have?
Mironid has approximately 16 people on record.